Background: Idiopathic inflammatory myopathies (IIM) are heterogeneous systemic autoimmune diseases with a worldwide incidence ranging from 0.116 to 1.9 and a prevalence from 2.4 to 33.8 per 100 000 inhabitants. Compared to other ethnicities, peculiarities such as younger age at diagnosis, increased risk of ILD, or more frequent cardiac involvement have been suggested in people of African descent. However, studies in this population are scarce and more data are needed, from epidemiology to patient characteristics and outcomes. Objectives: To describe the epidemiology, characteristics and evolution of patients with IIM in a population of almost 300,000 adults in the Caribbean Island of Martinique with free access to high-level socialized healthcare. Methods: We conducted a retrospective longitudinal study from January 1, 2000 to June 2023 at the University Hospital of Martinique, the island's only tertiary care center, which includes 2 national reference centers. Patients with an adult-onset IMM, including dermatomyositis (DM), polymyositis (PM), antisynthetase syndrome (ASyS), overlap myositis (OM), immune-mediated necrotizing myopathies (IMNM) and inclusion body myositis (IBM), were included if they met the criteria (Bohan & Peter for probable or definite PM or DM, Connor for ASyS, ENMC International Workshop for IMNM and IBM, and Troyanov's criteria for OM). Clinical, biological, and radiological characteristics were collected and compared between subtypes. Number of new diagnosis and living patients per year were used as numerator and total population of Martinique as denominator to calculate incidence and prevalence. Results: From January 1, 2000 to December 31, 2022, mean incidence of IIM was 2.34 per 100 000 person-year, and the global prevalence of IIM reached 33.2/100 000 inhabitants in 2022, with variations between subtypes (Table 1). A total of 174 patients (76.4% female) were included, of whom 55 (31.6%) had ASyS, 44 (25.3%) OM, 44 (25.3%) DM, 16 (9.2%) PM, 14 (8.1%) IMNM and 1 (0.6%) IBM. Patients were diagnosed within a median time of 4.2 months [IQR 2.0; 12.3] from first symptoms, and the median age at diagnosis was 52 [38.9; 61.8]. The median follow-up was 5.1 years [2.2; 10.8]. Initial and cumulative manifestations were inflammatory arthralgia, muscle weakness and skin DM lesions in 110 (65.1%), 95 (61.3%), and 89 patients (53.3%), respectively. Sixteen patients (29.1%) with ASyS had skin dermatomyositis lesions. At diagnosis, 77 (52%) and 28 patients (16.3%) had interstitial lung disease (ILD) and cardiac involvement, respectively. ASyS was more frequently clinically amyopathic (p<0.05) and had more frequently ILD (p<0.05) than other IIM subtypes. Anti-Jo1 antibody was the most frequent myositis specific autoantibody, followed by anti-PL12, and anti-SRP in 27 (16.0%), 21 (12.4%) and 11 (6.5%) patients, respectively. Sixty-nine patients (39.7%) relapsed at least once during follow up, in a median time of 2.8 years [1.1; 7.2]. Malignancy was diagnosed in 15 patients (8.6%) in a median time of 1.5 months [-24.0; 13.0]. 35 (20.1%) patients died during study period, without statistical differences between groups. Conclusion: The incidence and prevalence of IMM in the Caribbean island of Martinique appear to be higher than those reported in the literature. ASyS is the most common subtype, and rates of ILD and cardiac involvement at diagnosis also appear to be higher in this population than in other ethnic groups. On the other hand, IBM seems extremely rare. Further comparative data are needed to confirm these findings and decipher the pathophysiological mechanisms. Table 1. Incidence and prevalence/100 000 inhabitants of IIM according to subtypes in the Caribbean island of Martinique REFERENCES: [1] Meyer, A. et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology, 2015. [2] Chinniah, K. J. & Mody, G. M. The spectrum of idiopathic inflammatory myopathies in South Africa. Clin Rheumatol, 2021. [3] Chua, F. et al. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford), 2012. Acknowledgements: NIL. Disclosure of Interests: None declared.
No takes yet. Share an insight, caveat, or question.
Suzon et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: